Obesity in adults: a clinical practice guideline
By S. Wharton, D. Lau, M. Vallis, Arya M. Sharma, L. Biertho, D. Campbell-Scherer, K. Adamo, Angela Alberga, R. Bell, N. Boulé and 52 more. Canadian Medical Association Journal, 2020
1,184 citations recorded by the source corpus.
KEY POINTS Obesity is a complex chronic disease in which abnormal or excess body fat (adiposity) impairs health, increases the risk of long-term medical complications and reduces lifespan.[1][1] Epidemiologic studies define obesity using the body mass index (BMI; weight/height2), which can stratify
Subfields: Pharmacology, Pharmacy, Physiology
View Paper: https://www.semanticscholar.org/paper/e8e91e34da0231c37e2cf47fa5220218b31c4a5a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacy
In Physiology
Citations in the corpus
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. (2021, background): “Clinical guidelines suggest adjunctive pharmacotherapy, particularly for adults with a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or greater, or 27 or greater in persons with coexisting conditions.(1,2,10) However, the use of available medicati”
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. (2022, background): “Obesity is a chronicdisease associatedwithmultiple complications, including type 2 diabetes, nonalcoholic fatty liver disease, and cardiovascular disease, which place significant burdens on individuals and health care systems.(23-26) Treatment guidelines recommend 5% to 15% weight loss to improve th”